跳至主要内容
临床试验/CTRI/2012/10/003067
CTRI/2012/10/003067进行中(未招募)未知

A prospective, open label study assessing the 24-hour intraocular pressure pattern monitored by SENSIMED Triggerfish® in primary angle closure and primary angle closure glaucoma patients, before and after laser peripheral iridotomy

SENSIMED AG0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Diagnosis of primary angle closure (PAC) or primary angle closure glaucoma (PACG) with indication for LPI
  • a. PAC is defined by the presence of a partial or complete iridotrabecular contact (ITC) in more than 2 quadrants with either raised IOP (ie. more than 21 mmHg) and/or primary adhesion to the trabecular meshwork (peripheral anterior synechiae, PAS); however, with normal optic disc and visual field.
  • b. PACG is defined by the presence of ITC with either raised IOP and/or PAS, and evidence of glaucomatous optic disc and visual field.
  • 2) No IOP-lowering drug treatment or a 4-week wash-out period prior to SD0 and throughout the study
  • 3) Aged greater than or equal to 18 years, of either sex
  • 4) Not more than 6 diopters spherical equivalent on the study eye
  • 5) Not more than 2 diopters cylinder equivalent on the study eye
  • 6) Have given written informed consent, prior to any investigational procedure

排除标准

  • 1) History of acute angle closure glaucoma
  • 2) Secondary angle closure glaucoma
  • 3) History of penetrating ocular surgery within the last 3 months
  • 4) History of glaucoma surgery, including previous LPI
  • 5) Corneal or conjunctival abnormality precluding contact lens adaptation
  • 6) Severe dry eye syndrome
  • 7) Patients with allergy to corneal anesthetic
  • 8) Patients with contraindications for silicone contact lens wear
  • 9) Patients not able to understand the character and individual consequences of the investigation
  • 10) Participation in other clinical research within the last 4 weeks

研究者

发起方
SENSIMED AG

相似试验

未知
3 期
A 24 week, open label, multi-center evaluation of pharmacokinetics and pharmacodynamics, efficacy and safety of omalizumab in Japanese children (6-15 years) with inadequately controlled allergic asthma despite current recommended treatmentAllergic asthma
JPRN-jRCT2080221137ovartis Pharma K.K.44
进行中(未招募)
不适用
26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. - NAMedDRA version: 8.0Level: LLTClassification code 10039626Schizophrenia
EUCTR2005-005502-23-SEPfizer AB180
进行中(未招募)
不适用
26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. - NAMedDRA version: 8.0Level: LLTClassification code 10039626Schizophrenia
EUCTR2005-005502-23-DEPfizer Pharma GmbH180
尚未招募
1 期
An Initial Study for the Use of a New Cold Energy System (BXT-786) to Provide Pain Relief Through A Regional Block for Subjects with unrelieved pain related to severe osteoarthritis of the knee.knee painknee replacementOsteoarthritis (severe knee)Anaesthesiology - Pain managementSurgery - Other surgery
ACTRN12621001667808Brixton Biosciences Pty Ltd16
已完成
4 期
A clinical trial to see the effect of stapled anastamosis and Hand sutured anastamosis in patients undergoing gastrointestinal end to end and side to side anastamosis.
CTRI/2009/091/000311Johnson and Johnson Ltd300